MSK medical oncologist Nancy Kemeny

Nancy E. Kemeny, MD

Medical Oncologist

Clinical Expertise

Colorectal Cancer; Pseudomyxoma Peritonei; Islet Cell Cancer; Thymoma

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Accepted Insurance Providers

Dr. Kemeny accepts the following list of insurance providers. Select your insurance provider to see more details.

Contact and Location

Locations map

Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.

About Me


MD, University of Medicine and Dentistry of New Jersey


Internal Medicine - St. Luke's Hospital


Medical Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

Internal Medicine; Medical Oncology

I am a medical oncologist with a special expertise in developing new chemotherapy regimens for colorectal cancer. During my 30 years at Memorial Sloan Kettering, I conducted some of the first studies using drugs such as irinotecan (Camptosar®) and oxaliplatin (Eloxatin®), which are now widely used in patients with colorectal cancer. I was also the lead investigator of a large, multi-institutional study that helped in the Food and Drug Administration’s approval of oxaliplatin for colorectal cancer treatment in the U.S. My research has involved improving outcomes for people with liver metastases using regional chemotherapy. Regional chemotherapy involves administering drugs into an artery that feeds tumors in the liver. This can be done using an internally implanted pump called hepatic arterial infusion (HAI). The effectiveness of HAI regional chemotherapy given in combination with systemic chemotherapy has led to its use in patients with surgically resected (removed) liver metastases (also known at adjuvant treatment). This combination has decreased the recurrence of disease after liver resection.

A recent publication updated the survival of 287 patients who were treated on four adjuvant studies conducted at MSK from 1991 to 2009. All of the patients included in this analysis had their primary colon or rectal tumors removed and underwent surgery to remove the liver metastases and to place the HAI pump. Each study used different combinations of systemic chemotherapy, but all studies included HAI pumps.

The median follow up for all patients was 11 years and nine years for patients treated after 2003. Patients treated after 2003 with HAI combined with newer systemic chemotherapies had a 78% five-year survival and 61% ten-year survival.

New studies using this therapy have allowed patients with extensive liver disease who are not resectable to achieve an excellent response, which then allows resection. We have also used this treatment for patients with primary liver cancer.

Awards and Honors

  • Castle Connolly: New York Magazine Top Doctors (2002-2018)


Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

Clinical Trials

Smiling doctors in the lab

Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Research and Publications